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a database of 286 patients receiving EUS-FNA and the DNA test. Patients who had
pancreatic cysts and were not indicated for surgery by cytology alone were divided
into the four possible CEA-result groups using criteria that specifies5 is negative,
and 192 positive. The DNA test was considered positive if any of three compo-
nents (DNA quantity, K-ras mutation, and multiple allelic imbalance mutations)
were positive. RESULTS: Based on the database, 38.5% had insufficient fluid for
CEA. Of CEAs, 50% were positive, 21.6% negative, and 28.4% indeterminate. Proba-
bilities of a positive DNA test were 6.9% in patients with negative, 36.8% with
indeterminate, and 55.2% with positive CEAs, and 35.7% in patients with insuffi-
cient fluid. Including costs of cytology but not the EUS-FNA, costs were $381, $1575,
and $2642 per patient for the three strategies. Assuming the DNA is not specific
enough for a negative diagnosis, the costs per MPC diagnosis are $866, $2716, and
$4128 with 44%, 58%, and 64% being diagnosed. Positive diagnosis results in annual
follow–up with potential for surgical resection. CONCLUSIONS: Scenarios in which
negative DNA tests forego or reduce frequency of follow-up with minimal increase
in cancer risk are potentially cost-effective. However, if positive and indeterminate
diagnoses are treated similarly, the DNA test cost cannot be justified.
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OBJECTIVES: In the UK, anti-angiogenesis (AA) drugs (e.g. bevacizumab) have not
been accepted as good value for money within the general metastatic breast cancer
(MBC) population. However, it may benefit some subpopulations within MBC. An-
giogenesis-specific imaging tests (A-IT) under development have the potential to
offer earlier, accurate determination of response to AA therapies for MBC patients,
and lower treatment costs.METHODS:A decision-tree-based model was developed
to estimate the likely economic impact of A-IT from start of AA therapy through to
progression of disease. Key decision nodes were presence/absence of A-IT, sensi-
tivity/specificity (SE/SP) of A-IT, clinician adherence to test results and treat/no
treat decision. Key model inputs (and base case values): 1) median time to progres-
sion [TTP] for current MBC patients on AA therapies (9.5 months); 2) median TTP for
A-IT identified responders (13 months); 3) costs of bevacizumab, one cycle (£3,591);
4) costs of hemorrhaging, per event (£9,681); 5) per patient costs for diagnostic
(£3,826); 6) estimated SE/SP of diagnostic – 95%/75%; 7) clinician adherence to test
results (75%). RESULTS: Based on a hypothetical cohort of MBC patients, base case
results indicate that use of A-IT after just one cycle of AA therapy results in savings
of £3,570 per patient versus a scenario where A-IT was not used. One-way thresh-
old sensitivity analysis shows A-IT is cost-saving if SP  62% or when clinician
adherence is 63%. Results were insensitive to changes in SE. CONCLUSIONS:Use
of A-IT could allow for cost-effective use of AA therapies in subgroups of MBC
patients due to the earlier, more accurate determination of clinical benefit. Further
research is required to assess if A-IT allows AA therapy to become acceptably
cost-effective treatment for general MBC in the UK.
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OBJECTIVES: Patients with high risk early breast cancer (BC) frequently have adju-
vant therapy that includes taxane treatment (TAX) with a 28% reduction in risk of
relapse (BCIRG 001). TAX is associated with considerable toxicities which impact
quality-of-life and only a minority of patients derive benefit from the regimen.
Biomarkers to predict TAX-response may improve the equation of treatment/ad-
verse events costs with the benefits and risks to patients. Our objective is to exam-
ine the economic impact of adding a predictive TAX test for BC in a UK health care
setting. METHODS: A predictive model estimated the potential cost offsets of test-
ing a cohort of BC pts with a biomarker to guide therapy selection vs. no pretesting.
The no biomarker test group received 6 cycles of 3 weekly TAC: docetaxel (50mg/
m2) doxorubicin (50mg/m2), cyclophosphamide (500mg/m2) (cost £5944 generic
prices). In the biomarker tested (cost £606) cohort, only those with biomarker over-
expression received TAC. Assuming test predictivity of 70-90%, those found with-
out over-expression (50.3% - 64.7% based upon 71.9% with no improved disease free
survival from TAX trial findings, were treated with NICE guideline-recommended
FEC-60 X 6 cycles (£2213)). Each group accrued appropriate related therapy, toxicity
and biomarker test costs, with all costs taken from published sources. RESULTS:At
70-90% predictive, the model estimated £2991–£3846 of TAC therapy costs/patient
could be avoided along with £350-£450 of toxicity-related costs with the biomarker.
Taking alternative therapies and toxicities into account, potential cost offsets were
£2413-£3276. Patients without biomarker over-expression avoided TAC toxicities
and associated quality-of-life impacts. CONCLUSIONS: Applying a biomarker test
to identify women likely to respond to TAX appears to save drug costs and avoid
TAX-related toxicities.
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OBJECTIVES: Approximately 20% of metastatic renal cell carcinoma (mRCC) pa-
tients receiving 1st line (1LT) sunitinib experience disease progression (PD) identi-
fied by RECIST at 90 days post 1LT initiation. Earlier PD identification would mini-
mize futile1LT, facilitating a switch to potentially more effective 2nd line therapy.
Current research is evaluating biomarkers that identify rapid PD (rPD). This study’s
goal was to estimate the economic impact of utilizing an angiogenesis-specific
imaging (AI) biomarker for early PD identification. METHODS: An economic model
for mRCC patients receiving 1LT sunitinib from a UK National Health System per-
spective was developed with a 90 day time horizon. Comparator arm used RECIST
monitoring; the intervention arm an AI biomarker. Inputs included: timing of PD
assessment (day 14 for AI; day 90 for RECIST); sunitinib costs (£1,569 for 14 days;
£6,950 for 90 days); other 1LT costs (£468 for 14 days; £1,861 for 90 days); and rPD
rate of 20%. Outcomes included incremental length of futile 1LT and costs for AI vs.
RECIST. RESULTS: For AI sensitivity of 50%, a 38 day reduction in futile 1LT could be
achieved per rPD patient by using AI vs. RECIST (AI sensitivity of 75% or 100%
yielded 57 and 76 fewer days). Incremental cost savings reflecting resources that
could be freed up for AI utilization across all mRCC patients was £677, £1,016 and
£1,355 per patient for AI sensitivity of 50%, 75% and 100%. CONCLUSIONS: Pro-
longed therapy exposes non-responding patients to risks without potential clinical
benefit and results in misallocated health care resources which could be directed
elsewhere. Results of this study suggest that a diagnostic test enabling early PD
identification may reduce futile 1LT and its negative clinical/economic conse-
quences. Further research should evaluate additional benefits of early PD identifi-
cation, including improved patient quality of life and/or better clinical outcomes of
subsequent therapies.
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OBJECTIVES: Self-Monitoring of Blood Glucose (SMBG) is considered as a key factor
in management of people with diabetes which is a growing and cost demanding
health problem. The purpose of this study was to investigate the effect of compre-
hensive patient management using structured SMBG on metabolic control as well
as its cost consequence analysis. METHODS: Sixty subjects were recruited in an
observational study for a period of 6 months. They were provided with the ACCU-
CHEK 360° View tool to fill in the values of the 7-point blood glucose profiles in three
consecutive days during the study on a monthly basis. Changes in metabolic con-
trol were assessed by HbA1c and lipid profile measurement at the beginning and at
the end of the study. In addition, cost consequence analysis was done considering
different level of health care professionals with or without insurance coverage. The
Average Cost Effectiveness Ratio (ACER) as well as Cost Benefit Analysis (CBA) were
calculated and compared. RESULTS: The analysis showed significant reduction in
HbA1c during the 6-month period in all subjects (P0.000). Furthermore, a positive
effect was observed on lipid profile. The cost of endocrinologist’s visit in private
sector was estimated to be 265.76 USD while this figure was 149.15 USD for general
practitioner in public sector with insurance coverage. Total complications and
mortality cost saving was 154.8 USD. The lowest ACER was calculated for the in-
tervention done by general practitioner in public sector with insurance coverage.
CONCLUSIONS: Structured SMBG results in significant improvement of glycemic
status. Moreover, it is cost beneficial in public sector with insurance coverage. It
seems that general practitioner visits with insurance coverage is the most afford-
able option for people with type 2 diabetes.
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OBJECTIVES: The purpose of this medico-economic study is to estimate cost-effec-
tiveness impact of treating the patients suffering from venous leg ulcers in France.
Outpatient treatment with soft-adherent foam dressing with TLC-NOSF a healing
accelerator technology (Lipido-Colloid Technology, TLC, with Nano-OligoSaccha-
ride Factor, NOSF) was compared to the identical dressing without NOSF com-
pound (neutral foam dressing).METHODS:A lifetime Markov model based on three
states: “Patient with more than 6 months venous leg ulcer”, “Patient with healing
ulcer” and “Death”. The healing process is represented by a law of Gompertz. The
probability of recurrences is considered. Monte Carlo simulation of 1000 patients
was applied to compare face to face the situations which were not experimentally
tested. An intermediate endpoint of effectiveness was healing rate of ulcers during
8 weeks. A final health outcome was life-years gained without ulcers. We have
estimated the direct costs associated with material costs, medical consultation and
nursing care. This evaluation takes into account both health insurance and health
care system perspectives in France. Clinical and economic outcomes were dis-
counted at 4%. RESULTS: The number of life-years gained without ulcer is 5.8
(CI95%: [5.5;6.0]) years comparing with the dressing without NOSF. Additional
QALY gain is 1.3 [CI95%: 1.2; 1.3]. According to health care system perspective, the
mean cost per patient at lifetime period is €20119,322 [CI95%: €8,725; €9,920] com-
paring with €18,352 [CI95%: €17,807; €18,897] using the dressing of reference. The
probabilistic sensitivity analysis of 10,000 bootstrapping samples was performed
comparing two strategies. The estimated probability shows 100% of acceptability of
the treatment with TLC-NOSF technology. CONCLUSIONS: According to the base
case hypotheses the innovational strategy TLC-NOSF is more effective and less
costly than the reference dressing (neutral foam dressing).
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